Literature DB >> 25699290

Regenerative Medicine for the Aging Brain.

Micaela Lopez-Leon, Paula C Reggiani, Claudia B Herenu, Rodolfo G Goya.   

Abstract

In the central nervous system, cholinergic and dopaminergic (DA) neurons are among the cells most susceptible to the deleterious effects of age. Thus, the basal forebrain cholinergic system is known to undergo moderate neurodegenerative changes during normal aging as well as severe atrophy in Alzheimer's disease (AD). Parkinson's disease (PD), a degeneration of nigro-striatal DA neurons is the most conspicuous reflection of the vulnerability of DA neurons to age. In this context, cell reprogramming offers novel therapeutic possibilities for the treatment of these devastating diseases. In effect, the generation of induced pluripotent stem cells (iPSCs) from somatic cells demonstrated that adult mammalian cells can be reprogrammed to a pluripotent state by the overexpression of a few embryonic transcription factors (TF). This discovery fundamentally widened the research horizon in the fields of disease modeling and regenerative medicine. Although it is possible to re-differentiate iPSCs to specific somatic cell types, the tumorigenic potential of contaminating iPSCs that failed to differentiate, increases the risk for clinical application of somatic cells generated by this procedure. Therefore, reprogramming approaches that bypass the pluripotent stem cell state are being explored. A method called lineage reprogramming has been recently documented. It consists of the direct conversion of one adult cell type into another by transgenic expression of multiple lineage-specific TF or microRNAs. Another approach, termed direct reprogramming, features several advantages such as the use of universal TF system and the ability to generate a rejuvenated multipotent progenitor cell population, able to differentiate into specific cell types in response to a specific differentiation factors. These novel approaches offer a new promise for the treatment of pathologies associated with the loss of specific cell types as for instance, nigral DA neurons (in PD) or basal forebrain cholinergic neurons in the early stages of AD. The above topics are reviewed here.

Entities:  

Keywords:  Alzheimer; Parkinson; brain aging; cell reprogramming; direct reprogramming; iPSCs; neurodegeneration; regenerative medicine; transdifferentiation

Year:  2014        PMID: 25699290      PMCID: PMC4330563     

Source DB:  PubMed          Journal:  Enliven J Stem Cell Res Regen Med        ISSN: 2379-5751


  82 in total

1.  Region-specific differentiation of neural tube-derived neuronal restricted progenitor cells after heterotopic transplantation.

Authors:  H Yang; T Mujtaba; G Venkatraman; Y Y Wu; M S Rao; M B Luskin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

2.  Neural stem cells directly differentiated from partially reprogrammed fibroblasts rapidly acquire gliogenic competency.

Authors:  Takeshi Matsui; Morito Takano; Kenji Yoshida; Soichiro Ono; Chikako Fujisaki; Yumi Matsuzaki; Yoshiaki Toyama; Masaya Nakamura; Hideyuki Okano; Wado Akamatsu
Journal:  Stem Cells       Date:  2012-06       Impact factor: 6.277

Review 3.  Direct lineage reprogramming to neural cells.

Authors:  Janghwan Kim; Rajesh Ambasudhan; Sheng Ding
Journal:  Curr Opin Neurobiol       Date:  2012-05-30       Impact factor: 6.627

4.  Variation in the safety of induced pluripotent stem cell lines.

Authors:  Kyoko Miura; Yohei Okada; Takashi Aoi; Aki Okada; Kazutoshi Takahashi; Keisuke Okita; Masato Nakagawa; Michiyo Koyanagi; Koji Tanabe; Mari Ohnuki; Daisuke Ogawa; Eiji Ikeda; Hideyuki Okano; Shinya Yamanaka
Journal:  Nat Biotechnol       Date:  2009-07-09       Impact factor: 54.908

5.  A model for genetic and epigenetic regulatory networks identifies rare pathways for transcription factor induced pluripotency.

Authors:  Maxim N Artyomov; Alexander Meissner; Arup K Chakraborty
Journal:  PLoS Comput Biol       Date:  2010-05-13       Impact factor: 4.475

6.  Morphometry of the human substantia nigra in ageing and Parkinson's disease.

Authors:  Gay Rudow; Richard O'Brien; Alena V Savonenko; Susan M Resnick; Alan B Zonderman; Olga Pletnikova; Laura Marsh; Ted M Dawson; Barbara J Crain; Mark J West; Juan C Troncoso
Journal:  Acta Neuropathol       Date:  2008-02-23       Impact factor: 17.088

7.  Transplantation of primed or unprimed mouse embryonic stem cell-derived neural precursor cells improves cognitive function in Alzheimerian rats.

Authors:  Farshad Homayouni Moghadam; Hojatoallah Alaie; Khadije Karbalaie; Somayeh Tanhaei; Mohammad Hossein Nasr Esfahani; Hossein Baharvand
Journal:  Differentiation       Date:  2009-07-18       Impact factor: 3.880

Review 8.  Steps toward safe cell therapy using induced pluripotent stem cells.

Authors:  Hideyuki Okano; Masaya Nakamura; Kenji Yoshida; Yohei Okada; Osahiko Tsuji; Satoshi Nori; Eiji Ikeda; Shinya Yamanaka; Kyoko Miura
Journal:  Circ Res       Date:  2013-02-01       Impact factor: 17.367

9.  Direct cell reprogramming is a stochastic process amenable to acceleration.

Authors:  Jacob Hanna; Krishanu Saha; Bernardo Pando; Jeroen van Zon; Christopher J Lengner; Menno P Creyghton; Alexander van Oudenaarden; Rudolf Jaenisch
Journal:  Nature       Date:  2009-11-08       Impact factor: 49.962

10.  In vivo reprogramming of adult pancreatic exocrine cells to beta-cells.

Authors:  Qiao Zhou; Juliana Brown; Andrew Kanarek; Jayaraj Rajagopal; Douglas A Melton
Journal:  Nature       Date:  2008-08-27       Impact factor: 49.962

View more
  2 in total

Review 1.  Modeling Human Neurological and Neurodegenerative Diseases: From Induced Pluripotent Stem Cells to Neuronal Differentiation and Its Applications in Neurotrauma.

Authors:  Hisham Bahmad; Ola Hadadeh; Farah Chamaa; Katia Cheaito; Batoul Darwish; Ahmad-Kareem Makkawi; Wassim Abou-Kheir
Journal:  Front Mol Neurosci       Date:  2017-02-28       Impact factor: 5.639

Review 2.  Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Niemann-Pick Type C1.

Authors:  Christin Völkner; Maik Liedtke; Andreas Hermann; Moritz J Frech
Journal:  Int J Mol Sci       Date:  2021-01-12       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.